• Achieved $100m revenue milestone with 22% growth vs prior year
• EBITDA of $9.2m, up from $0.6m in prior year
• Positive operating and free cash flow, strengthening balance sheet

SomnoMed Ltd, a leading provider of oral appliance therapy for the treatment of sleep apnea, has reported its financial results for the full year ended 30 June 2025. The company delivered strong performance, achieving revenue of $111.5m, up 22% from the prior year. This was driven by double-digit growth across all regions, as the company continued to expand its manufacturing capacity and improve turnaround times. The company's EBITDA increased significantly to $9.2m, up from $0.6m in the prior year, with the EBITDA margin improving from 1% to 8%. This was achieved through disciplined cost management and operational efficiencies. SomnoMed also generated positive operating cash flow of $4.8m and free cash flow of $0.8m, strengthening its balance sheet with a cash balance of $17.3m.The company made progress on several key operational initiatives during the year, including a successful manufacturing overhaul, the FDA clearance of its Rest Assure compliance monitoring technology, and the appointment of a new management team and board members with additional sector, manufacturing and investment experience.

For FY26, SomnoMed expects revenue in the range of $119m to $126m and EBITDA between $10m and $12m. Capital expenditure is expected to be $6m to $8m, with a focus on expanding manufacturing capacity and further developing the Rest Assure technology.

Looking ahead, SomnoMed is focused on sustainable growth and investment, aiming to drive further revenue and margin expansion, expand its manufacturing capabilities, and advance the development of its innovative Rest Assure technology. The company is well-positioned to capitalize on the growing demand for oral appliance therapy as a CPAP alternative and to continue its transformation of the sleep medicine industry.